AnaptysBio, Inc.
(NASDAQ : ANAB)

( )
ANAB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.61%284.001.4%$846.81m
AMGNAmgen, Inc.
0.11%221.101.3%$516.31m
CELGCelgene Corp.
-0.03%109.991.3%$466.64m
GILDGilead Sciences, Inc.
-0.29%64.881.0%$399.18m
VRTXVertex Pharmaceuticals, Inc.
2.34%209.801.9%$313.89m
ILMNIllumina, Inc.
-1.10%302.613.5%$307.88m
REGNRegeneron Pharmaceuticals, Inc.
1.92%344.872.6%$267.68m
EXASEXACT Sciences Corp.
3.55%82.0524.0%$209.78m
ALXNAlexion Pharmaceuticals, Inc.
2.34%108.372.0%$179.80m
SGENSeattle Genetics, Inc.
1.29%114.756.1%$136.96m
BMRNBioMarin Pharmaceutical, Inc.
-0.71%75.044.3%$123.64m
SRPTSarepta Therapeutics, Inc.
0.05%97.4614.6%$115.38m
AAgilent Technologies, Inc.
1.95%78.261.6%$101.36m
NBIXNeurocrine Biosciences, Inc.
2.89%113.055.0%$90.40m
BGNEBeiGene Ltd.
0.94%198.252.1%$88.64m

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.